Arvinas
Kathy High Takes Helm at GV, ARCH-Backed Eye Disease Biotech RhyGaze; Arvinas Sees Leadership Shift
Kathy High, RhyGaze, GV, ARCH, eye disease biotech, Arvinas, leadership changes
Novartis Secures $1B Protein Degrader Deal with Arvinas and Initiates MorphoSys Tender Offer
Novartis, Arvinas, Protein Degrader Deal, PROTAC® Androgen Receptor Degrader, MorphoSys Tender Offer